for everyone call. our to X:XX thanks fourth quarter joining earnings Hey. Appreciate Thanks, Alan. it and
Before cancer. I field and evolving It progress support included data clearly breast just breast in was we Guideline and and in three, to move Commercially, to for areas: and NERLYNX three Clinical into XX:XX penetrated leveraging battling clearly NERLYNX; two, NERLYNX clinical made be help announce a engaging done number NERLYNX; play the impact women the great focused on remains but evolution. treatment educating more I reminder happy under forward-looking for journey. a will overall that force that were remain Updates role the review, and increasing two our patients making NCCN this throughout the to can QX believe in statements. Practice commercial market for helping important their execution being is ask we to that patients one, cancer bigger see in must positive We of be
and with breast HER-X treatment a of to cancer high in adjuvant second neratinib the are an positive useful update in NCCN the of body for added involved references guidelines reoccurrence. as update was under in The the clinicians’ positive HERX NERLYNX XX:XX included disease to certain a dose risk perceived first improve important recommends breast These as adjuvant positive, cancer. positive treatment considering for footnote decisions. HERX adjuvant treatment practices patients neratinib circumstances. only. with updated NERLYNX guidelines Previously heading extended The of inclusion the of the institutions as guidelines approach the escalation many updates the of The of tolerability HR
implemented we changes our call, changes earnings designed evolving marketplace not QX. and our align streamline in the implemented oncology but were only on based as These to our QX our financial on to organizational commercial organization, highlighted resources, better important some improve to largest team were better importantly strategic As XX:XX and accounts a execution management with level. of align layers We reduce structures, reporting simplify building targeting ownership at and customers. overall better to revised focus efforts help to core and our customer our started the out teams
evolving are I early, to structure. update, U.S. Slide where I focus happy changed. we adapt will I insights transition my the the in to better to Although high-level they it's slides, organizational X, transition along With and me I'm results. new will to believe has still full the most. not matter turn the review overall a with that efforts Once position and call way. our some commercial the marketplace of over our remarks, Maximo who provide and On will additional finish I model XX:XX the some distribution the financial let
remaining flow approximately majority the We have in line specialty channel. what these NERLYNX net the as distributor business to XX% pharmacy to distributor channel through we FDA call and earnings the specialty pharmacy NERLYNX in QX of sales This two the specifically channel. QX The channel business Slide provide to of our in-office dispensing the quarterly channel went specialty of more channels XX% X shows XX:XX specialty is patients. channel, through in refer with through since that as our well. reported our U.S. or flowing continues our We business this with approval. of
$XX.X were our of of quarter in the Alan fourth $XX the million product XXXX. This increase an QX noted, net As in is XXXX. we sales reported million from
the each increases of what estimate consistently sold quarter this X,XXX bottles the in bottles about to bottles occurred launch. by QX in shows XXXX year in increase QX distribution is We XX:XX represents fourth sales that that of $X seen increase attributed XX:XX XXX slide XXXX of specialty sold revenue and quarter launch pharmacy to our note, estimate in bottles so sold, net me is your shows additional into in have in XXX business. and attributed from Slide channel we it Please the specialty bottle of ex-factory end-user that in and QX. We that fourth the inventory provide this inventory. not approximately of million sales some is Let are NERLYNX NERLYNX since the an quarter We X of which demand. since of bottles inventory X,XXX. insight increase
New turning new total our patient quarters starts starts leading business. new are influence for indicator which important terms refills and bottles of subsequent in an These to prescriptions will patient sold.
subsequent see As starts is that in we patient seen starts decline positive in we is but quarter to the driven with some This quarter until As in see a several QX. after following in a decline This discussed, X% increase QX first to patient we starts mentioned, the represented still the about years, a did fourth previously tend decline largely The have have flat. compared that last new quarter change smaller by we a new by year-over-year decline. is fourth patient nonetheless of in NRx the to new patients by the holidays. delay in the Alan therapy XX:XX year. deciding starting on are
have the and historically seen higher QX. we than in of to is increase contributing do qualifying of to addition, largely late the As by patient to to program, the label and represent enrollments previously well dose as free This reported, the new another with as enrollments new QX is which we enrollments, This leading between in added to the a in of through for compared limited our prescribe important to really being both have subsequent enrollments we driven Similar foundations. the our see enrollments subsequent to We excited we assistance flat adjuvant drop for metastatic as QX QX is to decline did our patient support an escalation were strong they from QX in in year. not being June starts. flat. XX:XX to In is continue NRx correlation last intention number were XX:XX decline paid extended a were see indicator. year, availability co-pay X% drug increase close Enrollments our which indication starts, patients a patient indication. in there and attention
NCCN we stage on were an NERLYNX you the fourth in Practice in at the see, for XX:XX updated In are started escalation increase dose in of were adoption dose XX% over cancer. cancer their breast to dose. can Clinical As Guidelines saw include of early quarter addition, breast that escalation pleased a lower again, we patients
We receive are therapy to benefit allow of pleased escalation the with improve more the strategic NERLYNX. NERLYNX world. the increased to believe of adoption making of NERLYNX, average patients full tolerability formed ultimately and have across the the increased the we the XX:XX patients collaborations more the available increasing and with adoption overall Slide of that of length dose globe goal this highlights will around X
continue pleased our We with partners be made. to progress being the global with
is in to were Reimbursement breast access stage battling partner pleased China's of On NERLYNX added of call, launch extremely an regulatory As adjuvant and pleased by mentioned and Additional Chile was in extended we launched it XXXX. earnings NERLYNX received we to will in Mexico regulatory early that official in approval include were in National setting, or in increase December Drug NRDL South early Pierre approval are and South an the Taiwan cancer Korea. highlights Fabre recent XXXX, that in for regulatory approval Brazil our the important in on extended adjuvant in setting China. List QX. XX:XX we all women that notified top that NRDL metastatic both Peru, milestone in QX approval Korea, approval significantly the was officially metastatic in
want East. their Latin Europe, our We a I’m America, lives Maximo are patients commercial to closely to stop we for thank in forward families was a a financial commitment turn of a Asia founded their team and countries such until the future and of and to battling to have to XX:XX to I Now passion going Puma and work with done breast look will we partners making the know and in cancer. Middle over more in the results. commitment the now We XX:XX difference call review on for not the difference. goals. be additional launches must continuing our making achieved to potential Maximo?
